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its 60th anniversary since its establishment in 1948. The 60th
anniversary provides an excellent opportunity to undertake
a review in the past and a projection into the future. The
review will be beneﬁcial to the participants at the Inter-
national Conference to share one another’s experience as
tuberculosis remains a common problem in many parts of
the world.
Method: The methods used include a search of the
relevant ofﬁcial reports, documents, publications about
tuberculosis control in Hong Kong and personal interviews
with professionals in the academic and private sectors.
The author’s personal experiences as former Director of
Health, Hong Kong, will greatly enhance the values of the
review.
Results: The TB notiﬁcation rate has fallen from 697.2
per 100,000 population in 1952 to 90.4 per 100,000 in 2005.
The death rate from TB fell from 168.1 per 100,000 to 4.0
over the same period. The infant mortality rate from TB has
also fallen from 3.5 per 1000 registered live births in 1952 to
zero in 2005. The average age of TB deaths has lengthened
considerably from 25 in 1952 to 74.3 in 2005. Today Hong
Kong has already well exceeded the three targets for 2005
as set out by the WHO Regional Committee for the Western
Paciﬁc which included detecting 70% of estimated TB cases,
successfully treating 85% of these cases and making DOTS
accessible to 100% population.
Conclusion: Although Hong Kong has successfully con-
trolled TB in the past, there are new challenges in
the future, because of population movement, emergence
of MDR-TB and XDR-TB, and the problem of HIV/TB
co-infection. There is a need to strengthen the surveil-
lance system and intensify our efforts, particularly on
chemotherapy and laboratory services, responding to
HIV/TB co-infection and MDR-TB. Strong partnership with all
sectors at local, regional and international levels is essential
in our ultimate success on TB control.
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Introduction: The study has been performed in order to
search the species distribution and the resistance rates of
mycobacteria to antituberculous agents isolateded in the
region of Van.
Materials and Method: Identiﬁcation of strains have
been carried out through the method of DNA-hybridization
(Accu Probe-Gen Probe Levder, USA- hybridization device
and Accu Probe-Gen Probe, San Diego, California, USA-
Mycobacterium tuberculosis complex identiﬁcation test) for
the mycobacterium bacilli isolated by inoculating to Löven-
stein Jensen culture, an then by means of the E test
method (AB Biodisc, Sweden), the etambutol (ETB), strep-
tomisin (SM), isoniazid (INH) and rifanpin (RIF) resistance
of the species have been searched. Middle Brook 7 H9
Broth (Difco, USA) and Middle Brook 7 H10 agar (Difco,
USA) cultures were used for anti-tuberculosis drug resistance
tests.
Results: As the result of the study, while identifying the
species of the 25 tuberculosis bacilli isolated from the dif-
ferent patients which was performed through Gen Probe
method, it was determined that all of them were Mycobac-
terium tuberculosis. However, at the susceptibility test
carried out through E Test method, resistance was deter-
mined at the rate of 4% to ETB, and 8% to RIF. In none of the
strains was resistance determined against SM and INH.
Conclusion: The study is important because of its being
the ﬁrst study performed in order to determine the anti-
tuberculous drug resistance in the province of Van.
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Background: Although isoniazid is most efﬁcient in killing
the tuberculosis bacilli, resistance to this drug also devel-
ops most readily. Mutations in katG, inhA and ahpC are
responsible for isoniazid resistance in a large proportion of
tuberculosis cases. However, the frequency of these muta-
tions varies with population samples. This study provided
the ﬁrst molecular characterization of isoniazid resistance
of M. tuberculosis strains that is widely applicable for rapid
drug resistance detection.
Methods: The study was diagnostic-testing and pres-
ence of mutations in speciﬁc regions of the katG, inhA and
ahpC genes was analyzed with 32M.tuberculosis isoniazid-
resistant strains from Isfahan and Tehran. The katG
mutations in codon 315 associated with isoniazid resistance
among isoniazid resistant isolates was determined by PCR-
RFLP. In this way, 355 bp PCR products were digested by MspI
and MspA1I. Mutations in inhA and ahpC genes were detected
by sequencing
Results: Mutations in the katG 315(Ser→Thr), inhA and
ahpCwere detected in 71.9, 18.9 and 6.2% of the 32 isoniazid
resistant isolates, respectively. Mutations were not found in
one (%) of the isolates.
Discussion: The PCR-RFLP with MspI that detect katG
Ser315Thr substitution identiﬁed more isoniazid-resistant
strains with mutations at codon 315 in the katG. Elucidation
of the molecular basis of isoniazid resistance in M. tuber-
culosis has led to the development of different genotypic
approaches for the rapid detection of isoniazid resistance
in clinical isolates. The results also suggest that detection
of the Ser315Thr in the katG gene may be used as a rapid
screening method for identifying isoniazid-resistant clinical
